Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.

  • Authors:
    • S Monjanel-Mouterde
    • C Frenay
    • J Catalin
    • C Boutin
    • A Durand
    • P Astoul
  • View Affiliations

  • Published online on: January 1, 2000     https://doi.org/10.3892/or.7.1.171
  • Pages: 171-176
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We determined the toxicity and pharmacokinetics of high-dose intrapleural cisplatin (CDDP) as a treatment of malignant pleural effusions (MPE). Fourteen patients with MPE were enrolled in this study. After complete drainage of the fluid, a catheter was inserted into the pleural cavity during a thoracoscopy. CDDP (300 mg) was administered via the catheter in a 6-h infusion. Peak levels, the areas under the concentration curve (AUC), and drug half-lives were measured in pleural fluid and plasma samples collected at 0 (baseline), 6, and 24 h as well as 4, 14, and 21 days after intrapleural administration. The dosage of CDDP ranged from 153 to 203 mg/m2. The time interval between infusion was prolonged until a maximum of 109 days. Only 7/40 infusions were associated with adverse effects in 4 patients (18%). Residual concentrations in pleural fluid (0.66+/-0.07 microgram /ml) were three-fold higher than in plasma (0.13+/-0.07 microgram/ml). In pleural fluid, maximal concentration (Cmax) varied from 19 to 900 microgram/ml and in plasma from 0.34 to 3.65 microgram/ml. AUC in plasma during the three courses was 112+/-49 microgram/ml/d. The T1/2 was 31+/-33 days higher than that previously reported after intravenous administration (8-15 days). Although intrapleural CDDP has the potential advantage of treating the underlying malignancy in addition to controlling the malignant effusion with a good tolerance, it cannot be recommended for the standard control of malignant pleural effusion. Indeed we observed a great variability of intrapleural CDDP concentration depending on the extent of pleural invasion and plasma diffusion. Further studies are needed to determine the value of high-dose intrapleural CDDP for the treatment of MPE.

Related Articles

Journal Cover

Jan-Feb 2000
Volume 7 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Monjanel-Mouterde S, Frenay C, Catalin J, Boutin C, Durand A and Astoul P: Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.. Oncol Rep 7: 171-176, 2000
APA
Monjanel-Mouterde, S., Frenay, C., Catalin, J., Boutin, C., Durand, A., & Astoul, P. (2000). Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.. Oncology Reports, 7, 171-176. https://doi.org/10.3892/or.7.1.171
MLA
Monjanel-Mouterde, S., Frenay, C., Catalin, J., Boutin, C., Durand, A., Astoul, P."Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.". Oncology Reports 7.1 (2000): 171-176.
Chicago
Monjanel-Mouterde, S., Frenay, C., Catalin, J., Boutin, C., Durand, A., Astoul, P."Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.". Oncology Reports 7, no. 1 (2000): 171-176. https://doi.org/10.3892/or.7.1.171